(130 days)
Not Found
Yes
The device description explicitly mentions the use of a Convolutional Neural Network (CNN) model, which is a type of deep learning, a subset of machine learning.
No
The device is described as software for image analysis and quantification to aid clinicians in assessment and diagnosis, rather than directly treating or preventing a disease or condition.
Yes
Explanation: The device "aids clinicians in the assessment and quantification of pathologies" and "supports the accuracy of the medical professional's diagnosis of dementia," which indicates its role in identifying and understanding diseases.
Yes
The device description explicitly states "The Veuron-Brain-pAb3 is a standalone software". The summary focuses entirely on software functionalities, image processing, and the use of a CNN model, with no mention of accompanying hardware components or hardware-specific validation.
Based on the provided information, this device is likely NOT an IVD (In Vitro Diagnostic).
Here's why:
- IVD Definition: In Vitro Diagnostics are tests performed on samples taken from the human body (like blood, urine, or tissue) to detect diseases, conditions, or infections. They are used to provide information for diagnosis, monitoring, or screening.
- Device Function: The Veuron-Brain-pAb3 software analyzes medical images (MRI and PET) of the brain. It processes these images to calculate metrics like SUVR and aids in the visualization and analysis of amyloid protein concentration.
- Lack of Sample Analysis: The software does not analyze biological samples taken from the patient. Its input is medical imaging data, not in vitro samples.
- Focus on Image Analysis: The core function is image processing, registration, fusion, and analysis, which falls under the category of medical image analysis software, not IVD.
- Intended Use: The intended use is to aid clinicians in the assessment and quantification of pathologies from PET Amyloid scans, supporting diagnosis but not performing a diagnostic test on a biological sample itself.
While the software provides information that supports a medical professional's diagnosis, it does so by analyzing imaging data, not by performing a test on a biological specimen. This distinction is key to the definition of an IVD.
No
The provided text does not contain any explicit statement that the FDA has reviewed and approved or cleared a Predetermined Change Control Plan (PCCP) for this specific device.
Intended Use / Indications for Use
Veuron-Brain-pAb3 is software for the registration, fusion, display, and analysis of medical images from multiple modalities including MRI and PET. The software aids clinicians in the assessment and quantification of pathologies from PET Amyloid scans of the human brain. It enables anatomic analysis and visualization of amyloid protein concentration through the calculation of standard uptake volume ratio (SUVR) within target reqions of interest and comparison to those within the reference regions. The software is deployed via medical imaging workplaces and is organized as a series of workflows which are specific to use with radio-tracer and disease combinations.
Product codes
LLZ
Device Description
The Veuron-Brain-pAb3 is a standalone software for quantitative analysis of the PET amyloid by automatically calculating the "Standardized Uptake Value Ratio (SUVR)". The calculated result is only used as a reference to support the accuracy of the medical professional's diagnosis of dementia in patients. It also helps with accurate visual interpretation through visualization functions. Various PET amyloid images can be processed by using diverse options provided for users to choose in the image process.
Mentions image processing
Yes
Mentions AI, DNN, or ML
Yes
- Convolutional Neural Network (CNN) model.
Input Imaging Modality
MRI and PET
Anatomical Site
Brain
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Clinicians in the assessment and quantification of pathologies from PET amyloid scans of the human brain / Hospital
Description of the training set, sample size, data source, and annotation protocol
CNN model has trained 3D brain MR images were collected from one domestic institution.
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Software verification and validation was performed to demonstrate the new functions perform as intended. No clinical testing was conducted.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s)
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 892.2050 Medical image management and processing system.
(a)
Identification. A medical image management and processing system is a device that provides one or more capabilities relating to the review and digital processing of medical images for the purposes of interpretation by a trained practitioner of disease detection, diagnosis, or patient management. The software components may provide advanced or complex image processing functions for image manipulation, enhancement, or quantification that are intended for use in the interpretation and analysis of medical images. Advanced image manipulation functions may include image segmentation, multimodality image registration, or 3D visualization. Complex quantitative functions may include semi-automated measurements or time-series measurements.(b)
Classification. Class II (special controls; voluntary standards—Digital Imaging and Communications in Medicine (DICOM) Std., Joint Photographic Experts Group (JPEG) Std., Society of Motion Picture and Television Engineers (SMPTE) Test Pattern).
0
Image /page/0/Picture/0 description: The image contains the logos of the Department of Health & Human Services and the Food and Drug Administration (FDA). The Department of Health & Human Services logo is on the left, and the FDA logo is on the right. The FDA logo includes the agency's name, "U.S. Food & Drug Administration," in blue text.
October 13, 2023
Heuron Co., Ltd. % John J. Smith, M.D., J.D. Partner Hogan Lovells US LLP Columbia Square 555 Thirteenth Street NW Washington, District of Columbia 20004
Re: K231642
Trade/Device Name: Veuron-Brain-pAb3 Regulation Number: 21 CFR 892.2050 Regulation Name: Medical Image Management And Processing System Regulatory Class: Class II Product Code: LLZ Dated: September 13, 2023 Received: September 13, 2023
Dear John Smith:
We have reviewed your section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (the Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database available at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
1
Additional information about changes that may require a new premarket notification are provided in the FDA guidance documents entitled "Deciding When to Submit a 510(k) for a Change to an Existing Device" (https://www.fda.gov/media/99812/download) and "Deciding When to Submit a 510(k) for a Software Change to an Existing Device" (https://www.fda.gov/media/99785/download).
Your device is also subject to, among other requirements, the Quality System (QS) regulation (21 CFR Part 820), which includes, but is not limited to, 21 CFR 820.30. Design controls; 21 CFR 820.90. Nonconforming product; and 21 CFR 820.100, Corrective and preventive action. Please note that regardless of whether a change requires premarket review, the QS regulation requires device manufacturers to review and approve changes to device design and production (21 CFR 820.30 and 21 CFR 820.70) and document changes and approvals in the device master record (21 CFR 820.181).
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR Part 803) for devices or postmarketing safety reporting (21 CFR Part 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR Part 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR Parts 1000-1050.
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems.
2
For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).
Sincerely,
D. Rayfield
Daniel M. Krainak, Ph.D. Assistant Director DHT8C: Division of Radiological Imaging and Radiation Therapy Devices OHT8: Office of Radiological Health Office of Product Evaluation and Quality Center for Devices and Radiological Health
Enclosure
3
Indications for Use
510(k) Number (if known) K231642
Device Name Veuron-Brain-pAb3
Indications for Use (Describe)
Veuron-Brain-pAb3 is software for the registration, fusion, display, and analysis of medical images from multiple modalities including MRI and PET. The software aids clinicians in the assessment and quantification of pathologies from PET Amyloid scans of the human brain. It enables anatomic analysis and visualization of amyloid protein concentration through the calculation of standard uptake volume ratio (SUVR) within target reqions of interest and comparison to those within the reference regions. The software is deployed via medical imaging workplaces and is organized as a series of workflows which are specific to use with radio-tracer and disease combinations.
| Type of Use (Select one or both, as applicable) |
|---|
| ☒ Prescription Use (Part 21 CFR 801 Subpart D) |
— Over-The-Counter Use (21 CFR 801 Subpart C)
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
*DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW. *
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration
Office of Chief Information Officer
Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of
information unless it displays a currently valid OMB number."
4
510(k) SUMMARY Heuron Co., Ltd.'s Veuron-Brain-pAb3
Submitter Information Company Name: Heuron Co., Ltd. Address:10F, C, 150, Yeongdeungpo-ro, Yeongdeungpo-gu, Seoul, 07292, Republic of Korea
Contact Person: John J. Smith, M.D., J.D. Phone: +1 202 637 3638 Facsimile: +1 202 637 5910 Date Prepared: September 5, 2023
Name of Device: Veuron-Brain-pAb3 Common or Usual Name: Medical Imaging Software Classification Name: System, Image Processing, Radiological Regulatory Class: 21 CFR 892.2050 Product Code: LLZ
Predicate Device
Manufacturer name: Heuron Co., Ltd. Device's trade name: Veuron-Brain-pAb2 510(K) number: K213801 Regulatory Class: 21 CFR 892.2050 Product Code: LLZ
Device Description
The Veuron-Brain-pAb3 is a standalone software for quantitative analysis of the PET amyloid by automatically calculating the "Standardized Uptake Value Ratio (SUVR)". The calculated result is only used as a reference to support the accuracy of the medical professional's diagnosis of dementia in patients. It also helps with accurate visual interpretation through visualization functions. Various PET amyloid images can be processed by using diverse options provided for users to choose in the image process.
Intended Use / Indications for Use
The Veuron-Brain-pAb3 is a software for the registration, display and analysis of medical images from multiple modalities including MRI and PET. The software aids clinicians in the assessment and quantification of pathologies from PET amyloid scans of the human brain. It enables automatic analysis and visualization of amyloid concentration through the calculation of standard uptake value ratio (SUVR) within target regions of interest and comparison to those within the reference regions. The software is deployed via medical imaging workplace and is organized as a series of workflows which are specific to use with radio tracer and disease combinations.
Summary of Technological Characteristics
Image load and SUVR calculation is the technological principle for both the subject and predicate devices. Both devices load the MR and PET images, and calculate SUVR for the brain. At a high level, the subject and predicate devices are based on the following same technological elements:
5
- Image load ●
- Overlay .
- SUVR calculation ●
- Report .
The following technological differences exist between the subject and predicate devices:
- . Addition of a worklist. Veuron-Brain-pAb3 includes a worklist showing the user of the list of patients.
- . Addition of a tracer option. With Veuron-Brain-pAb3, users can select the tracer for beta amyloid. By providing an option (reference region) for tracer, helps users identify appropriate brain regions for analysis.
| Subject device | Predicate device (K213801) | |
|---|---|---|
| Device name | Veuron-Brain-pAb3 | Veuron-Brain-pAb2 |
| Manufacturer | Heuron Co., Ltd. | Heuron Co., Ltd. |
| Product code | LLZ | LLZ |
| Indications for use | The Veuron-Brain-pAb3 is software for | |
| the registration, fusion, display, and | ||
| analysis of medical images from multiple | ||
| modalities including MRI and PET. The | ||
| software aids clinicians in the | ||
| assessment and quantification of | ||
| pathologies from PET Amyloid scans of | ||
| the human brain. It enables anatomic | ||
| analysis and visualization of amyloid | ||
| protein concentration through the | ||
| calculation of standard uptake volume | ||
| ratio (SUVR) within target regions of | ||
| interest and comparison to those within | ||
| the reference regions. The software is | ||
| deployed via medical imaging | ||
| workplaces and is organized as a series | ||
| of workflows which are specific to use | ||
| with radio-tracer and disease | ||
| combinations. | The Veuron-Brain-pAb2 is software | |
| for the registration, fusion, display, | ||
| and analysis of medical images from | ||
| multiple modalities including MRI | ||
| and PET. The software aids | ||
| clinicians in the assessment and | ||
| quantification of pathologies from | ||
| PET Amyloid scans of the human | ||
| brain. It enables automatic analysis | ||
| and visualization of amyloid protein | ||
| concentration through the calculation | ||
| of standard uptake volume ratio | ||
| (SUVR) within target regions of | ||
| interest and comparison to those | ||
| within the reference regions. The | ||
| software is deployed via medical | ||
| imaging workplaces and is organized | ||
| as a series of workflows which are | ||
| specific to use with radiotracer and | ||
| disease combinations. | ||
| Target anatomical site | Brain | Brain |
| Where used | Hospital | Hospital |
| Design features | Import DICOM data | |
| Perform automatic post-processing | ||
| Provide the user confirmation | ||
| Export the resulting data through a | ||
| network or USB | Import DICOM data. | |
| Perform automatic post-processing. | ||
| Provide the user confirmation | ||
| Export the resulting data through a | ||
| network or USB | ||
| Physical characteristics | Software package | Software package |
| Subject device | Predicate device (K213801) | |
| Operates on off-the-shelf hardware | ||
| (multiple vendors) | Operates on off-the-shelf hardware | |
| (multiple vendors) | ||
| Operating system | Server: Linux (Ubuntu 18.04 LTS or | |
| higher) | ||
| Client: Windows 10 or higher | Server: Ubuntu 16.04 LTS or higher | |
| Client: Windows 10, 64-bit | ||
| Standards | ISO 14971 | |
| IEC 62304 | ||
| IEC 62366 | ISO 14971 | |
| IEC 62304 | ||
| IEC 62366 | ||
| Software verification and validation | Tested in accordance with verification | |
| and validation process and planning. The | ||
| testing results support that all the system | ||
| requirements have met their acceptance | ||
| criteria and are adequate for its intended | ||
| use. | Tested in accordance with | |
| verification and validation processes | ||
| and planning. The testing results | ||
| support that all the system | ||
| requirements have met their | ||
| acceptance criteria and are | ||
| adequate for its intended use. | ||
| Compatible input data format and | ||
| modality | DICOM & NIfTI | |
| PET, MRI | DICOM & NIfTI | |
| PET, MRI | ||
| Input patient data | Manual through keyboard/mouse | Manual through keyboard/mouse |
| Output patient data | Picture: PNG | |
| Report: PNG, csv | Picture: PNG | |
| Report: csv | ||
| Study list functionality | Search | |
| Importing | ||
| Exporting | Search | |
| Importing | ||
| Exporting | ||
| Worklist | Yes | No |
| Yes, can select the tracer for beta amyloid | No, cannot select the tracer for beta | |
| amyloid | ||
| Tracer option | Tracer list | |
| • 18F-Flutemetamol (FMM) | ||
| • 18F-Florbetapir (FBP) | ||
| • 18F-Florbetaben (FBB) | ||
| Segmentation Algorithm | • Calculate the volume by using a | |
| Convolutional Neural Network | ||
| (CNN) model. | ||
| • CNN model has trained 3D brain MR | ||
| images were collected from one | ||
| domestic institution | • Calculate the volume by using a | |
| Convolutional Neural Network | ||
| (CNN) model. | ||
| • CNN model has trained 3D | ||
| brain MR images were collected | ||
| from one domestic institution. |
A table comparing the key features of the subject and predicate devices is provided below.
6
Non-Clinical Performance Testing
Software verification and validation was performed to demonstrate the new functions perform as intended. No clinical testing was conducted.
Conclusions
The Veuron-Brain-pAb3 is as safe and effective as the Veuron-Brain-pAb2. The Veuron-Brain-pAb3 has the same intended uses and indications, it has similar technological characteristics, and principles of operation as its predicate device. In addition, the minor technological differences between the Veuron-Brain-pAb3 and its predicate devices raise no new issues of safety or effectiveness.